Looking to the future for erectile dysfunction therapies

Drugs
Konstantinos Hatzimouratidis, Dimitrios Hatzichristou

Abstract

The treatment of erectile dysfunction (ED) has been revolutionized during the last 2 decades with several treatment options now available. Most of these treatments are associated with high efficacy rates and favourable safety profiles. A MEDLINE search was undertaken to evaluate all currently available data on treatment modalities for ED. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice treatment option for ED by most physicians and patients. In addition, several new PDE5 inhibitors are candidates to enter the market in forthcoming years (avanafil, udenafil, SLx-2101, mirodenafil [SK3530]). However, obvious pharmacokinetic differences that result in a faster time-to-onset, longer half-life time and better safety profile are required for these drugs to be considered a truly better option for patients. Other molecules in development include selective dopamine, glutamate, serotonin and melanocortin receptor agonists, guanylate cyclase activators, rho-kinase inhibitors and hexarelin analogues, while the first trials on gene therapy and tissue engineering for reconstruction of corporal tissue are under way. Patients must be aware of all treatment options since no ideal tre...Continue Reading

Citations

Jul 2, 2010·Reproduction, Fertility, and Development·E M LuqueM Fiol de Cuneo
Nov 3, 2012·JAAPA : Official Journal of the American Academy of Physician Assistants·Reamer L Bushardt, Mark E Archambault
Feb 2, 2013·Therapeutic Advances in Urology·George T KediaKnut Albrecht
Nov 17, 2011·Drug Design, Development and Therapy·Amjad AlwaalSerge Carrier
Dec 3, 2013·Pharmacology, Biochemistry, and Behavior·K DecaluwéJ Van de Voorde
Nov 6, 2009·Current Opinion in Urology·Chunyu Wang
Aug 7, 2009·Nature Reviews. Urology·Ahmed Magheli, Arthur L Burnett
Sep 9, 2009·Nature Reviews. Urology·Sergei Kusmartsev, Johannes Vieweg
Sep 13, 2011·Expert Opinion on Therapeutic Patents·Andrew S Bell, Michael J Palmer
May 2, 2008·Expert Opinion on Investigational Drugs·Andrew Feifer, Serge Carrier
Oct 14, 2010·Expert Opinion on Investigational Drugs·Ma LiminWayne J G Hellstrom
Mar 2, 2012·La Presse médicale·André CormanNaji Gehchan
Dec 14, 2011·Maturitas·Steve K Williams, Arnold Melman
May 31, 2011·The Urologic Clinics of North America·Erin R McNamara, Craig F Donatucci
Aug 14, 2010·Primary Care·Victor A Diaz, Jeremy D Close
May 18, 2010·European Urology·Konstantinos Hatzimouratidis
Dec 20, 2008·Journal of Pharmaceutical and Biomedical Analysis·Sang Kyu LeeHye Hyun Yoo
Jun 4, 2015·Journal of Medicinal Chemistry·Jeremy GreenSteve Rodems
Apr 23, 2015·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Tae Kon KimOui Hyun Jung
Jan 3, 2012·International Journal of Pharmaceutics·Hyun-Jong ChoDae-Duk Kim
Jul 18, 2012·European Journal of Pharmacology·Chaweewan JansakulYouwapa Sukpondma
Sep 30, 2016·Expert Opinion on Pharmacotherapy·Igor VoznesenskyWayne J G Hellstrom
Oct 4, 2016·Expert Opinion on Drug Metabolism & Toxicology·Jeong Hee HongIsaac Yi Kim
Jul 19, 2015·American Journal of Men's Health·Douglas A MataRanjith Ramasamy
Nov 14, 2019·British Journal of Pharmacology·Nikolaos TzoumasDavid J Webb
Sep 25, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Sunita BabbarKeith Bley
Jan 16, 2009·International Journal of Immunopathology and Pharmacology·L SperanzaA Patruno
Mar 20, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Fangjun ChenPing Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.